Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirkwood, John M., Del Vecchio, Michele, Weber, Jeffrey, Hoeller, Christoph, Grob, Jean-Jacques, Mohr, Peter, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Mackiewicz, Jacek, Rutkowski, Piotr, Arenberger, Petr, Quereux, Gaelle, Meniawy, Tarek M., Ascierto, Paolo A., Menzies, Alexander M., Durani, Piyush, Lobo, Maurice, Campigotto, Federico, Gastman, Brian, Long, Georgina V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667090/
https://www.ncbi.nlm.nih.gov/pubmed/37845511
http://dx.doi.org/10.1038/s41591-023-02583-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667090/
https://www.ncbi.nlm.nih.gov/pubmed/37845511
http://dx.doi.org/10.1038/s41591-023-02583-2

Ejemplares similares